Form 4: Aprea Therapeutics Director Receives Equity Compensation Package

Aprea Therapeutics, Inc. Director Bernd R. Seizinger was granted 1,045 restricted stock units and 4,185 stock options on June 5, 2025, as part of his compensation.

Summary

• Bernd R. Seizinger, a Director of Aprea Therapeutics, Inc. (APRE), acquired 1,045 shares of common stock and 4,185 stock options.
• The 1,045 common stock shares represent restricted stock units (RSUs) granted on June 5, 2025, with a grant price of $0.00. These RSUs are scheduled to vest and be settled in common stock on June 5, 2026, contingent upon Mr. Seizinger's continued service on the Issuer's board of directors.
• The 4,185 stock options were granted on June 5, 2025, with an exercise price of $1.81 and a grant price of $0.00. These options will vest in full on June 5, 2026, also subject to his continued service on the board.
• Following these reported transactions, Mr. Seizinger beneficially owns 45,775 shares of common stock and 4,185 stock options.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a director, which is a positive for aligning management incentives with shareholder interests, but does not contain new operational or financial performance data that would significantly alter the company's outlook.

Positives

• The grant of restricted stock units and stock options to Director Bernd R. Seizinger aligns his financial interests with those of shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard and effective practice for retaining and motivating experienced board members in publicly traded companies.

Future Outlook

The restricted stock units and stock options granted to Director Bernd R. Seizinger are scheduled to vest on June 5, 2026, contingent upon his continued service on the board of directors, aligning future incentives with company performance.

Industry Context

The grant of equity compensation to a director is a common practice in the biotechnology and pharmaceutical industry, aiming to align the interests of board members with long-term shareholder value creation. Such grants are a standard component of executive and director compensation packages across publicly traded companies, reflecting a commitment to attracting and retaining experienced leadership.

Comparison to Industry Standards

• The structure of the equity grant, including restricted stock units and stock options with a vesting period tied to continued service, is consistent with typical director compensation practices observed in the U.S. biotechnology sector.
• While specific values of equity grants vary by company size, stage of development, and individual performance, the mechanism of aligning director incentives through equity is a globally recognized benchmark for corporate governance and compensation.

Related Party Transactions

• The grant of restricted stock units and stock options to Bernd R. Seizinger, a director of Aprea Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value, potentially leading to more focused governance and strategic decisions.
• Employees: While not directly impacting general employees, such compensation practices reflect the company's overall approach to incentivizing key personnel and leadership.

Next Steps

• Vesting of restricted stock units and stock options on June 5, 2026, subject to continued board service.

Key Dates

Recommendation

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, SEC Filing